Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pulmonary arterial hypertension].

D Montani1, X Jaïs, O Sitbon

  • 1Centre des Maladies Vasculaires Pulmonaires, UPRES EA2705, Service de Pneumologie et Réanimation respiratoire, Hôpital Antoine-Béclère, Université Paris-Sud, Assistance Publique, Hôpitaux de Paris, Clamart, France.

Revue Des Maladies Respiratoires
|November 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the shunt: Divergent insights from hyperoxia testing and contrast echocardiography in adults with pulmonary hypertension.

Physiological reports·2025
Same author

Pulmonary hypertension in connective tissue diseases: What every CTD specialist should know - but is afraid to ask!

La Revue de medecine interne·2023
Same author

[Genetic counselling and testing in pulmonary arterial hypertension - A consensus statement on behalf of the International Consortium for Genetic Studies in PAH - French version].

Revue des maladies respiratoires·2023
Same author

[Lung transplantation for severe pulmonary hypertension].

Revue des maladies respiratoires·2023
Same author

[Updated indications and contraindications in 2022 for lung transplantation in France].

Revue des maladies respiratoires·2022
Same author

[French practical guidelines for the diagnosis and management of IPF - 2021 update, full version].

Revue des maladies respiratoires·2022
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Pulmonary arterial hypertension (PAH) management has improved with new therapies. Novel drugs offer new treatment options, but their precise role in PAH management requires further investigation.

Area of Science:

  • Cardiology
  • Pulmonary Medicine
  • Pharmacology

Background:

  • Pulmonary arterial hypertension (PAH) is a rare, progressive condition leading to right heart failure.
  • PAH is classified as idiopathic, familial, or secondary to other conditions.
  • Echocardiography is used for initial detection, with right-heart catheterization for diagnosis confirmation.

Purpose of the Study:

  • To review the current understanding and management of Pulmonary Arterial Hypertension (PAH).
  • To discuss the evolution of PAH treatment strategies.
  • To highlight emerging therapeutic perspectives in PAH management.

Main Methods:

  • Review of current literature on PAH classification and diagnosis.
  • Analysis of conventional and advanced treatment modalities for PAH.

Related Experiment Videos

  • Discussion of novel drug classes and their potential impact on PAH therapy.

    • Main Results:

    • Conventional treatments include warfarin, diuretics, oxygen, intravenous epoprostenol, bosentan, or prostacyclin analogues.
    • Recent advances in PAH management have significantly improved patient prognosis.
    • Novel specific drugs, such as type 5 phosphodiesterase inhibitors, are emerging.

    Conclusions:

    • The prognosis for PAH patients has markedly improved due to recent management advances.
    • Novel specific drugs offer promising therapeutic perspectives for PAH.
    • Understanding PAH mechanisms has driven treatment evolution from vasodilators to antiproliferative agents.